Kornimate/medical-research-clean huggingface dataset:
hyperlipidemia therapy tercet zabrze registry

Conditions: Hyperlipidemias; Secondary Prevention

Summary: a study conducted to evaluate the efficacy of lipid-lowering therapy in patients with high and very high risk treated by interventional cardiology. study endpoints: 1. achievement of the target ldl-c at 1-year follow-up ldl-c \<70 mg / dl in the group of very high-risk and ldl-c \<100 mg / dl in high-risk patients 2. assessment of the lipid profile of the severity of coronary artery disease in patients undergoing invasive diagnosis of coronary artery disease 3. evaluation of trends in the treatment of lipid-lowering in patients in different years

the tercet zabrze registry is an observational study of all patients hospitalized due to the cardiovascular diseases. the date include information on the hyperlipidaemia treatment, clinical characteristics, any treatment modalities and prognosis in this population. data collection is patient-based (not event-based). the study population is formed by all-comer patients hospitalized in cardiology wards and intensive cardiac care units with a diagnosis of coronary disease, both stable angina, and acute coronary syndromes (acs). for the purpose of this study hyperlipidaemia is defined in accordance with european society of cardiology guidelines. complete patient demographics; medical history, complete hospitalization data (diagnostic and therapeutic), in-hospital and out-hospital results are collected in an electronic form by the attending physician. the patients are under constant follow-up for all cause mortality and major adverse events.

Eligibility criteria:
inclusion criteria: * all patients with coronary artery disease with hyperlipidemia exclusion criteria: * no coronary artery disease

Keywords: hyperlipidemias secondary prevention high risk patients very high risk patients
testing spread and implementation of novel methicillin resistant staphylococcal aureus (mrsa)-reducing practices

Conditions: Blood Stream Infections; MRSA Infections

Summary: the purpose of this study is to implement strategies for improved efficiency and waste reduction ("toyota lean") and positive deviance, a social behavioral change process, utilizing frontline healthcare personnel to reduce infection bloodstream infection and mrsa infection in outpatient dialysis care. in two outpatient dialysis units, dialysis unit healthcare staff will be educated in toyota lean techniques and conduct periodic "discovery and action" dialogues to identify and implement care process changes to reduce infection. outcomes to be monitored will include incidence of bloodstream infections and mrsa infections of all types. data will be assessed at quarterly intervals using interrupted time series analysis.


Eligibility criteria:
inclusion criteria: all hemodialysis patients at two outpatient dialysis units exclusion criteria:peritoneal dialysis patients

Keywords: mrsa bloodstream infections hemodialysis
can mindfulness and self-monitoring improve control over maladaptive daydreaming?

Conditions: Internet-Based Intervention; Psychological Intervention; Intervention Study

Summary: maladaptive daydreaming (md) is a compulsive form of daydreaming that causes distress and functional impairment among tens of thousands of self-diagnosed sufferers. this is the first controlled treatment trial for md. the investigators built an internet-based self-help program for md and tested the effectiveness of mindfulness and self-monitoring in improving control over md, comparing three groups across three measurement points in time.

objective: maladaptive daydreaming (md) is a compulsive form of daydreaming that causes distress and functional impairment among tens of thousands of self-diagnosed sufferers. this is the first controlled treatment trial for md. method: the investigators built an internet-based self-help program for md and tested the effectiveness of mindfulness and self-monitoring in improving control over md, compared to internet-based support as usual (waiting-list group). participants were randomly assigned to three groups and measured across three points in time (baseline, post-intervention, and 6 months follow-up). the investigators measured the change in daydreaming pathology (mds-16), daydreaming frequency (ddfs), and daydreaming functioning (dwsas), alongside changes in psychiatric symptoms (bsi), and intervention outcome (oq). changes in mindful attention and awareness skills, compliance with program requirements, and feedback to the program were also measured.

Eligibility criteria:
inclusion criteria: * age above 18 years * md diagnosis * not being in any concurrent treatment for md * english fluent * daily access to the internet, and to a device with internet access * give informed consent to the study * respondents who reported being on a stable dose of medication for at least three months could take part in the study provided that they did not change their dosages while participating in the study. exclusion criteria: * age under 18 years * no md diagnosis * in concurrent psychology therapy for md * not fluent in english * not having a daily internet access * taking medication for less than three months

Keywords: maladaptive daydreaming immersive daydreaming absorption dissociation behavioral addiction compulsive behavior rct
phase iii study to evaluate the efficacy and safety of agsavi in patients with essential hypertension

Conditions: Hypertension

Summary: a phase 3 study to evaluate efficacy and safety of agsavi

a randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of agsavi for inadequately controlled with agls

Eligibility criteria:
inclusion criteria: * hypertension patient who satisfied below condition at visit 1. * patient who takes antihypertensive drug * 140mmhg \<= sitsbp \<= 200mmhg * patient who doesn't take antihypertensive drug * 160mmhg \<= sitsbp \<= 200mmhg * hypertension patient who satisfied below condition at visit 2. * 140mmhg \<= sitsbp \<= 200mmhg at visit 2 * 130mmhg \<= sitsbp \<= 200mmhg at visit 2(in high-risk patients) exclusion criteria: * patient who have received 4 or more antihypertensive drug * patient with 20mmhg of difference in sitsbp or 10mmhg of difference in sitdbp between 2 times of bp measuring at visit 1 * patient with sitdbp \>= 120mmhg at visit 1 or 2 * patient with secondary hypertension
efficacy and safety of ruxolitinib in neuromyelitis optica spectrum disorders

Conditions: Neuromyelitis Optica Spectrum Disorder Relapse

Summary: neuromyelitis optica spectrum disorders (nmosd) is associated with a pathological humoral immune response against the aquaporin-4(aqp-4) water channel. rucotinib is an oral inhibitor of jak1 and jak2 tyrosine kinases. it may benefit some patients with nmosd due to the important role of jak/stat signaling pathway in the pathogenesis of nmosd. clincial trials may be needed to observe its efficacy and safety.


Eligibility criteria:
inclusion criteria: male or female patients ≥ 18 years old; diagnosis of nmo or nmo spectrum disorder according to the 2015 international diagnostic criteria for neuromyelitis optic; clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last 24 months; edss \<= 6.0; rituximab should be used for at least 3 months if the condition is stable; able and willing to give written informed consent and comply with the requirements of the study protocol. exclusion criteria: current evidence or known history of clinically significant infection (herpes simplex virus, varicella-zoster virus, cytomegalovirus, epstein-barr virus, human immunodeficiency virus, hepatitis viruses, syphilis, etc); participation in another interventional trial within the last 3 months; patients taking oral immunosuppressants such as azathioprine; tumor disease currently or within last 5 years; pregnant, breastfeeding, or child-bearing potential during the course of the study; clinically relevant anemia, thrombocytopenia and dysfunction of the heart, liver, kidney or bone marrow.
4-week, multiple-dose, dose-escalating study in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: this is a dose-escalating study in patients with type 2 diabetes on metformin. participants will receive an investigational product or placebo for 28 days.


Eligibility criteria:
inclusion criteria: * type 2 diabetes treated with a stable dose of metformin at least 500 mg * hba1c value between 7.0 and 10.5% exclusion criteria: - type 1 diabetes or secondary forms of diabetes

Keywords: type 2 diabetes mellitus
modified enhanced recovery after oblique lateral interbody fusion surgery

Conditions: Lumbar Spondylosis; Lumbar Spinal Stenosis; Lumbar Disc Herniation

Summary: the goal of this randomized clinical trial is to investigate whether modified enhanced recovery after surgery (eras) in oblique lumbar interbody fusion (olif) can shorten the postoperative hospital stay among patients with lumbar degenerative disease. the main questions it aims to answer are: whether eras can shorten the postoperative hospital stay. whether modified eras can improve postoperative functional recovery, improve functional score and pain score, reduce hospitalization costs, improve mental state, and improve abdominal indicators, etc. participants will be randomized into modified eras group, or control group.

the main questions it aims to answer are: whether eras can shorten the postoperative hospital stay. whether modified eras can improve postoperative functional recovery, improve functional score and pain score, reduce hospitalization costs, improve mental state, and improve abdominal indicators, etc. participants will be randomized into modified eras group, or control group.

Eligibility criteria:
inclusion criteria: * age 18-80 years old; * lumbar degenerative diseases that meet the indications of fusion surgery; * patients who are suitable for olif surgery; * patients who have actually completed olif surgery; * the number of fusion segments is less than or equal to two; * there was no basis for serious diseases of brain, lung, kidney and other important organs, and preoperative american society of anesthesiologists (asa) score was i-iii; * agree to participate in the study and sign the informed consent form. exclusion criteria: * patients undergoing lumbar fusion surgery due to spinal trauma; * patients undergoing lumbar fusion surgery due to spinal tumor resection; * revision surgery; * the number of fused segments is more than 2; * simultaneous lumbar fusion via other approaches, such as transforaminal lumbar interbody fusion (tlif), posterior lumbar interbody fusion (plif), anterior lumbar interbody fusion (alif), etc.; * pregnancy or perinatal period; * blood system diseases lead to coagulation dysfunction; * combined with other diseases, life expectancy less than 2 years; * patients is participating in other clinical trials.
irritable bowel syndrome and food sensitivity

Conditions: Irritable Bowel Syndrome

Summary: the primary objective of the clinical trial portion of this study is to assess whether an individualized dietary plan based on a commercial food sensitivity assay provides specific benefit in a randomized controlled trial in adults with irritable bowel syndrome (ibs).

this is a parallel group, randomized control trial, powered to assess changes in validated outcomes in adult patients with symptomatic irritable bowel syndrome. subjects will receive dietary counseling and be asked to adhere to dietary instructions for 4 weeks. assessments will occur at baseline, 4-weeks, and 8-weeks post-baseline.

Eligibility criteria:
inclusion criteria: * between 18-70 years of age. * irritable bowel syndrome by rome iii criteria. * stable dose (30 days) of concurrent ibs medications * agree not to make significant changes to their diet during the study * ibs-sss score of \>150 exclusion criteria: * history of major abdominal surgeries * history of inflammatory bowel disease * antibiotic use within 1 month of enrollment * radiation proctitis or other known poorly controlled medical conditions that could interfere with bowel function * current use of opioid pain medications (except for nsaids) * previous experience participating in dietary studies for ibs * current use of medications which are known to be affected by modest dietary changes * vitamin c use of \>2000 mg/day * quercetin use of \>500 mg/day

Keywords: irritable bowel syndrome ibs diet food sensitivity
study of bgb-11417 monotherapy in participants with relapsed or refractory mantle cell lymphoma

Conditions: Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma (MCL); Relapsed Mantle Cell Lymphoma

Summary: the study consists of two parts. part 1 determines the safety and tolerability of bgb-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended phase 2 dose of bgb-11417 monotherapy for relapsed or refractory mantle cell lymphoma. part 2 evaluates efficacy of bgb-11417 monotherapy at the recommended phase 2 dose with recommended ramp-up schedule from part 1.


Eligibility criteria:
key inclusion criteria: 1. histologically confirmed diagnosis of mcl 2. prior systemic treatments for mcl (at least one line of anti-cluster of differentiation 20 (anti-cd20) based immune or chemoimmunotherapy and at least one kind of covalent or non-covalent adequate bruton tyrosine kinase (btk) inhibitor). 3. relapsed/refractory disease 4. presence of measurable disease 5. availability of archival tissue confirming diagnosis of mcl, or willing to undergo fresh tumor biopsy 6. eastern cooperative oncology group (ecog) performance status of 0,1 or 2. 7. adequate organ function key exclusion criteria: 1. known central nervous system involvement by lymphoma 2. prior malignancy other than mcl within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized gleason score 6 prostate cancer. 3. prior exposure to a bcl-2 inhibitor (eg, venetoclax/abt-199). 4. prior autologous stem cell transplant within the last 3 months; or prior autologous chimeric antigen receptor t-cell therapy within the last 3 months; or prior allogeneic stem cell transplant within the last 6 months or currently has an active graft-vs-host disease requiring the use of immunosuppressants. 5. clinically significant cardiovascular disease. 6. major surgery or significant injury ≤ 4 weeks prior to start of study treatment. 7. active fungal, bacterial or viral infection requiring systemic treatment. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: mantle cell lymphoma lymphoma mcl refractory mcl refractory mantle cell lymphoma relapsed mantle cell lymphoma
effect of memantine on cognitive impairment in patients with epilepsy

Conditions: Epilepsy

Summary: evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy

epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy. excito-toxicity, mediated by glutamate acting on n-methyl-d-aspartate (nmda) receptors in the hippocampus, can cause memory dysfunction in epilepsy . memantine is a low-affinity voltage-dependent uncompetitive antagonist of the nmda-type glutamate receptor . it also has antioxidant property and increases production of brain derived neurotropic factor (bdnf)

Eligibility criteria:
inclusion criteria: * patients with idiopathic epilepsy. * normal brain imaging (ct brain). * patients on anti epileptic drugs more than 6 months. * no more than two fits per month. * score of mini mental state examination (10-24), mild and moderate cognitive impairment. * no other medical disorders. exclusion criteria: * progressive neurological diseases. * abnormal brain imaging (ct brain). * more than two fits per month. * patients with severe cognitive impairment, score of mmse less than10. * patients with severe medical disorders
micronutrient supplementation and incidence of common cold

Conditions: Immune System Diseases

Summary: this study investigates the effects of a dietary supplement - a cocktail of vitamins and minerals - on the incidence of common cold in a cohort of middle management employees.the primary outcome is defined as the number of duty days lost due to common cold/flu. further, immune parameters and markers of redox biology/oxidative stress will be determined. the wellbeing in the cohort will be evaluated via questionnaires.

randomized, double-blinded, placebo controlled trial 82 subjects, men and women, 25 - 50 yrs, non-smokers, employees of middle management, 24 weeks of supplementation/placebo, 4 wk wash-out of all supplements and dietetic products, undersupply of fruit, vegetables (\< 4 portions/day) and whole grain food (\< 5x/wk)

Eligibility criteria:
inclusion criteria: * pre or peri-menopausal * non-smokers * sedentary or moderately trained * bmi: \>20 and \< 35kg/m2 * undersupply of fruits, vegetables and whole grain food, fibres * contraceptives * wash-out exclusion criteria: * post-menopausal * smokers * trained people * bmi out of inclusion range * adequate intake of vegetables, fruits and whole grain food, fibres * no adherence to wash-out

Keywords: common cold, immunity, oxidative stress
slpi for prostate cancer

Conditions: Prostate Cancer; Prostatic Neoplasm

Summary: exploratory study of slpi expression in human prostate cancer patients this is a no-profit exploratory study about the expression of slpi in human prostate cancer patients that will enroll about 200 patients admitted for suspect prostate cancer to careggi university hospital. we will verify whether an increase slpi levels in the sera may serve as biomarker of cancer progression.

prostate cancer (pc) is a heterogeneous disease that occurs more frequently in elderly men. prostate cancer is usually localized and it has a slow progression; thus, the patient may not suffer from any symptom for years. however, a proportion of patients pc develops metastases and may become a clinically relevant disease that can show an aggressive behavior and, eventually, give metastases. in any event, since it is the most common male cancer in the western countries, it is the second leading cause of cancer deaths in males. for this reason the identification of the molecular alterations determining the different clinical behaviors and of the associated biomarkers would be extremely useful. the secretory leukocyte protease inhibitor (slpi) is a serine protease which best-defined function is to protect host tissues from the excessive damage by proteolytic enzymes released during inflammation. recently slpi has been found overexpressed in a variety of cancers (pancreatic, papillary thyroid, uterine cervix, endometrial, and ovarian cancer). in apparent contrast, slpi has been found reduced in the sera (and tumor tissue) of prostate cancer patients in the respect of healthy subjects and of subjects with benign hyperplasia. however, slpi has been found upregulated in castration resistant prostate cancer (crpc) patients and in a subset of crpc cell lines. these data suggest that expression of slpi in prostate cancer could be biphasic: underexpressed during the early stages and overexpressed during progression. this peculiar pattern of slpi expression suggests that slpi may play a role in prostate cancer pathogenesis and/or in determining its neoplastic features. in this respect, it is noteworthy that slpi is located at 20q13.2 (hpc20 locus), a locus harboring prostate cancer susceptibility genes. based on these data it is possible to hypothesize that prostate cancer progression could be associated, and possibly heralded, by the increase of slpi. this is an observational investigation of slpi levels in blood and tissue samples of patients with prostate disease with the explorative goal to verify whether slpi could be a potential biomarker of prostate cancer progression.

Eligibility criteria:
inclusion criteria: * patients with prostate carcinoma. * patients with benign prostatic hyperplasia. * male subjects older that 50 years without prostate or neoplastic diseases. exclusion criteria: * male subjects younger that 50 years without prostate disease. * male subjects with neoplastic diseases either than prostate.

Keywords: prostate slpi prostate cancer
identification of tt cases by community treatment assistants: an assessment

Conditions: Trichiasis

Summary: to achieve the goal of trachoma control as mandated by the world health organization, countries must reduce the backlog of trichiasis surgery cases to less than 1/1,000 of their population. however, these cases reside in rural villages in trachoma endemic districts, and finding them to offer services is a challenge. community treatment assistants (ctas) are village residents who are trained to offer mass drug administration (mda) to their communities and hence are in contact with most residents. a training guide and tool for screening for trachomatous trichiasis (tt) will be developed to train ctas in rural tanzania to identify cases in their communities and refer them to surgery. compared to the current process by which ctas passively screen for tt if cases complaint, investigators hypothesize that the trained ctas will identify twice the usual number of tt surgery cases during ongoing community antibiotic administrations for trachoma and will also miss fewer cases. if this simple system is effective, it can be implemented widely to screen communities for cases of tt. residents from thirty-six villages holding mda, for whom a complete census is available, will be randomized on a 1:1 basis to intervention (where the ctas receive the enhanced training from the enhanced training team) and usual assessment (where the ctas receive the usual instructions from the regular mda team). in both arms, the ctas will keep records of all cases they have screened as positive for tt amongst the residents. a master tt grader will grade all screened cases of tt to determine the rate of true positivity in both arms.in addition, he will examine a random sample of residents who are screened as negative to detect potentially missed cases and estimate the total burden of trichiasis cases in both arms as well.the assessments of the master tt grader will serve as the gold standard for calculations of sensitivity, specificity, and positive and negative predictive values of the enhanced training versus usual assessment methods.


Eligibility criteria:
inclusion criteria: * all persons in the study and control communities are eligible for the mda. * adults aged 15 and over will be eligible for the survey and re-assessment. * those who are screened positive in the re-assessment will be eligible for treatment at the surgery camp. * those who are screened positive for tt initially but refuse the definitive re-screening will still be offered surgery but told they may not have tt and will be re-screened by the surgeon. exclusion criteria: * none

Keywords: trichiasis trachoma mass treatment